Samrat Pharmachem Faces Financial Challenges Amidst Strong Management Efficiency Metrics

Samrat Pharmachem, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment that reflects notable shifts in its financial metrics. The company reported a flat financial performance for the quarter ending March 2025, with a significant decline in its score over the past three months.
Key indicators reveal that the Profit After Tax (PAT) for the nine-month period stands at Rs 5.04 crore, while the quarterly PAT has dropped to Rs -0.40 crore, marking a substantial change compared to the previous four-quarter average. Additionally, the PBDIT for the quarter is reported at its lowest level of Rs 0.12 crore, and the operating profit to net sales ratio is also at a low of 0.17%.

Despite these challenges, Samrat Pharmachem maintains a high management efficiency, evidenced by a Return on Capital Employed (ROCE) of 27.61% and a low Debt to EBITDA ratio of 0.44 times. The company’s valuation appears attractive with a Price to Book Value of 1.7, indicating it is trading at fair value relative to its peers.

Overall, the recent evaluation adjustment highlights the complexities within Samrat Pharmachem's financial landscape, influenced by both operational performance and market dynamics.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.